Gilead’s HIV Products Target Of Subpoena From DoJ
This article was originally published in The Pink Sheet Daily
Executive Summary
Marketing and educational programs are the focus of inquiry from the U.S. Attorney’s Office in San Francisco, but the probe does not include the recently approved combination Atripla.
You may also be interested in...
Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy
The Bristol/Gilead combination product will launch within seven business days.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.